1. Michelson Diagnostics

    0 Comments Leave a Comment

    1-15 of 200 1 2 3 4 ... 12 13 14 »
    1. Mentioned In 200 Articles

    2. Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis

      Michelson Diagnostics launches new improved version of VivoSight OCT scanner with Micro-Camera to aid skin cancer diagnosis
      ... EADV on Thursday 9 th October, Room E106, 17:00 18.30. About Michelson Diagnostics and the VivoSight System Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam...
      Read Full Article
    3. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment

      Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment

      BACKGROUND: Patients with moderate to severe rosacea often seek treatment to reduce erythema and vascular markings. Few studies have looked at the effectiveness of the novel treatment, brimonidine topical gel 0.33%, trademark name Mirvaso®, in the treatment of rosacea. We report the use of optical coherence tomography (OCT) scanning to monitor the effectiveness of Mirvaso® on in vivo skin. OCT is a non-invasive optical imaging technique that can provide high-resolution imaging of vessel and cellular morphology. OCT may be useful as a pre-treatment assessment tool for identifying possible morphologic features in the skin that may serve as outcome predictors ...

      Read Full Article
    4. Feature Of The Week 6/8/14: Automated Registration of OCT and Dermoscopy in the Assessment in Basal Cell Carcinoma

      Feature Of The Week 6/8/14: Automated Registration of OCT and Dermoscopy in the Assessment in Basal Cell Carcinoma

      Optical coherence tomography (OCT) has been shown to be of clinical value in imaging basal cell carcinoma (BCC). A novel dual OCT-video imaging system, providing automated registration of OCT and dermoscopy, has been developed to assess the potential of OCT in measuring the degree of sub-clinical spread of BCC. Seventeen patients selected for Mohs micrographic surgery (MMS) for BCC were recruited to the study. The extent of BCC infiltration beyond a segment of the clinically assessed pre-surgical border was evaluated using OCT. Sufficiently accurate (<0.5 mm) registration of OCT and dermoscopy images was achieved in 9 patients. The location ...

      Read Full Article
    5. New study on non-invasive diagnosis of non-melanoma skin cancer with Melanoma Institute of Australia

      New study on non-invasive diagnosis of non-melanoma skin cancer with Melanoma Institute of Australia
      ...isation and mortality . Cat no. CAN 39. September 2008. Ab out the VivoSight System and Michelson Diagnostics Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam...
      Read Full Article
    6. Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT

      Positive top line results from clinical trial for diagnosis of basal cell carcinoma using VivoSight OCT
      ...lished in a leading peer review journal later this year. About Michelson Diagnostics and the VivoSight System Michelson Diagnostics has developed a world-leading, patented, medical imaging technology, known as multi-beam...
      Read Full Article
    7. Positive results from multi-centre, prospective clinical trial for diagnosis of basal cell carcinoma using Michelson Diagnostics’ VivoSight OCT Presented at AAD

      Positive results from multi-centre, prospective clinical trial for diagnosis of basal cell carcinoma using Michelson Diagnostics’ VivoSight OCT Presented at AAD
      ...t the skin, and in particular non-melanoma skin cancer. For further information come and meet the team at the Michelson Diagnostics booth, number 2255 - http://show.aad.org/annual14/EC/forms/attendee/indexTab.aspx

      Read Full Article
    8. Motion tracking to enable pre-surgical margin mapping in basal cell carcinoma using optical imaging modalities: initial feasibility study using optical coherence tomography

      Motion tracking to enable pre-surgical margin mapping in basal cell carcinoma using optical imaging modalities: initial feasibility study using optical coherence tomography

      A system has been developed to assess the feasibility of using motion tracking to enable pre-surgical margin mapping of basal cell carcinoma (BCC) in the clinic using optical coherence tomography (OCT). This system consists of a commercial OCT imaging system (the VivoSight 1500, MDL Ltd., Orpington, UK), which has been adapted to incorporate a webcam and a single-sensor electromagnetic positional tracking module (the Flock of Birds, Ascension Technology Corp, Vermont, USA). A supporting software interface has also been developed which allows positional data to be captured and projected onto a 2D dermoscopic image in real-time. Initial results using a stationary ...

      Read Full Article
    9. 1-15 of 200 1 2 3 4 ... 12 13 14 »
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Michelson Diagnostics

    Michelson Diagnostics

    Michelson Diagnostics.  Microscopy Systems.  Michelson Diagnostics Ltd (MDL) is a healthcare company providing a live view of cancerous tissue.  The company was formed in March 2006 to develop a hand-held cancer scanner based on an imaging technology called optical coherence tomography (OCT).   The patented device will give clinicians and researchers a live view of sub-surface tissue structures at near-cellular resolution - high enough to see the emergence and growth of cancer. It shows tissue as deep as 2 mm and offers much higher image resolution than ultrasound or MRI.  The non-invasive cancer scan reduces the need for painful and costly biopsies and provides patients and doctors with immediate results. Whole organs can be systematically scanned for abnormalities.

  3. Quotes about Michelson Diagnostics

    1. I found the MedTech Tour Summit extremely useful: the high standard of presenting companies at different stages of their business development provided insights into how I need to position Michelson Diagnostics for an investment. I also made contact with several interested investors and advisors, and discussions are progressing.
      Jon Holmes in Michelson Diagnostics is Singled Out for Growth
    2. Michelson Diagnostics has applied their outstanding technology to forward thinking products and I am extremely pleased to be representing the company in the US.
      Kevin C. Oakley in Michelson Diagnostics Opens US Offices And Appoints US Business Development Manager
    3. This is a remarkable milestone for Michelson Diagnostics, as it shows, through a statistically significant sample, that multi-beam OCT technology has the potential to play an important role in the early diagnosis of cancer.
      Jon Holmes in Michelson Diagnostics Reports First Quantitative Results on Cancer Diagnosis Using Multi-beam OCT imaging